Doomenor t1_jeevyew wrote on March 31, 2023 at 2:43 PM

Reply to Barcelona flood by jlg-photographs

It’s like a Dali painting

Doomenor t1_je2d4ea wrote on March 28, 2023 at 10:18 PM

Reply to Lock Stock and Two Expresso Shots by CantStopPoppin

Is there a place where open carrying a loaded fully automatic assault rifle is legal, even in the US??

Doomenor t1_jd5g5hl wrote on March 21, 2023 at 11:30 PM

Reply to There are a bunch of spare aircraft tires under the gate at my airport by porcelainvacation

Someone was too tired to move them

Doomenor t1_jd5fxsg wrote on March 21, 2023 at 11:29 PM

Reply to comment by NinjaMoreLikeANonja in Hi! I am the Chief Engineer of SBUDNIC, a 3U cubesat which is deorbiting itself via drag sail, AMA! by NinjaMoreLikeANonja

Wow that’s impressive

Doomenor t1_jd5eh2i wrote on March 21, 2023 at 11:18 PM

Reply to Hi! I am the Chief Engineer of SBUDNIC, a 3U cubesat which is deorbiting itself via drag sail, AMA! by NinjaMoreLikeANonja

How does a sail work in space where there is no atmosphere? Why a cube and not a sphere?

Doomenor t1_j2dmh3j wrote on December 31, 2022 at 1:57 PM

Reply to ELI5: Why is half-life so essential for drugs and not the whole time? by [deleted]

Generalizing A LOT, because we need to know how often we administer the medication in order to have a stable concentration. We need to do that not when it is completely cleared but when it is still active.

Doomenor t1_ixhff06 wrote on November 23, 2022 at 1:53 PM

Reply to Those beautiful clouds! by MLAuncle

Blood has been spilled tonight

Doomenor t1_ir78pxn wrote on October 5, 2022 at 9:00 PM

Reply to Study: Cannabis Preparations Associated with Quality of Life Improvements in Adults with Autism by BoundariesAreFun

“Results: Seventy-four patients with ASD were included in the analysis. The mean age of participants was 32.7 (±11.6) years. There were significant improvements in general health-related quality of life and sleep as assessed by the EQ-5D-5L, SQS and GAD-7 at 1 and 3 months, with sustained changes in EQ-5D-5L and SQS at 6 months (p < 0.010). There were 180 (243.2%) adverse events reported by 14 (18.9%) participants. If present, adverse events were commonly mild (n = 58; 78.4%) or moderate (n = 81; 109.5%), rather than severe (n = 41; 55.4%).

Conclusion: This study demonstrated an associated improvement in general health-related quality of life, and anxiety- and sleep-specific symptoms following initiation of treatment with CBMPs in patients with ASD. These findings, while promising, are limited by the confines of the study which lacks a control arm and is subject to attrition bias. Therefore, further evaluation is required with randomised controlled trials.”